TGen News & Press Releases

Wendy’s® franchisee’s Jr. Frosty® fundraiser benefits TGen cancer research

Posted Monday April 4, 2022

Fundraising starts today at nearly 200 Wendy’s in 10 states, including more than 60 locations across Arizona

TGen-Temple review suggests even normal weight individuals are susceptible to severe fatty liver disease

Posted Thursday March 24, 2022

Risk factors could include diet, genetics and ethnicity; no global consensus on how to screen for potentially deadly liver conditions

Could diet modification make chemotherapy drugs more effective for patients with pancreatic cancer?

Posted Monday March 21, 2022

Laboratory experiments at Princeton University and TGen, testing a ketogenic diet, lead to nationwide clinical trial

TGen, HonorHealth and Irish biomedical team initiate promising ‘Nieto’ clinical trial against pancreatic cancer

Posted Friday March 18, 2022

Named for a respected Arizona scientist, this trial uses a combination of drugs against advanced cancer in patients where other treatments have failed

‘Purple Pansies’ donates $1 million in support of TGen pre-clinical study

Posted Wednesday February 23, 2022

Disrupting cancer cells’ ability to formulate proteins could open door to improved treatment of pancreatic cancer

TGen partners with Deepcell to advance detection, analysis and treatment of disease

Posted Tuesday February 22, 2022

Technology platform provides state-of-the-art imaging and analysis of individual cells

Understudied lncRNAs could help enable early detection of potentially deadly liver disease

Posted Tuesday February 8, 2022

TGen-Temple comprehensive review highlights recently discovered associations between long noncoding RNAs and specific diseases

TGen-led international team identifies genes associated with suicide

Posted Monday January 10, 2022

Analysis of molecular-level biological changes could lead to better predictive models that would enhance assessment of suicide risk

TGen-UArizona medical school study points to possible new treatment options for breast cancer patients

Posted Wednesday December 22, 2021

Cxcl10 protein can indicate both positive and negative directions of cancer trajectory

TGen helps develop analysis tool, leading to more-accurate evaluation of new brain tumor treatments and individual estimates of survival

Posted Monday December 20, 2021

‘Nomograms’ accounting for sex differences in the design of clinical trials should help deliver new precision treatments to glioblastoma patients

Prev
1
2
3
4
[5]
Next

Media Contact

Galen Perry
[email protected]
602-343-8423

News Archive

View Media Release Archive

TGen is a partner with OncLive

Media Contact

Newsletter

News Archive

Latest Posts

Useful Links

Contact Us

Stay up-to-date with TGen